BACE1 and Alzheimer disease: In general, and on the basis of the published data relating to the effects of the oral BACE1 inhibitors in transgenic mouse models of AD, it can be concluded that BACE1 inhibitors are able to reduce the levels of Aβ in brain and CSF in a dose-dependent manner, but there is no solid evidence that they can improve cognitive functions effectively.